SAN DIEGO,Calif.--(BUSINESS WIRE)--Guardion Health Sciences, Inc. (“Guardion” or the “Company”), a leader in the field of ocular health technologies and products, announced that the Company’s CEO and founder, Michael Favish, and the Company’s Chief Science Officer and director, David W. Evans, are scheduled to present at the Planet Microcap Showcase 2018 (www.planetmicrocapshowcase.com) at the Planet Hollywood Resort & Casino in Las Vegas, Nevada in the Showcase’s Track 4 presentations on Wednesday afternoon at 2:00 P.M. (local time), April 25, 2018. The event is organized by Stock News Now and is being held on April 24 to 26, 2018. Mr. Favish and Dr. Evans will be available for one-on-one meetings with Showcase attendees on all three days.
Guardion CEO and founder, Michael Favish, commented, “Guardion acquired VectorVision in September 2017. I look forward to this opportunity to brief investors as to how this acquisition is impacting our combined operations, as well as the contributions we are making to ocular health.”
The slides and video presentation by Mr. Favish and Dr. Evans will be accessible on the day of the presentation using the following link: www.GuardionHealth.com/PlanetMicrocap2018.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. is an ocular health sciences company that develops, formulates and distributes condition-specific medical foods, with an initial medical food product that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”), and a significant component of functional vision performance. Guardion Health Sciences, Inc. has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence based protocol for the treatment of a depleted macular protective pigment.
VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent Form 10-K filed with the Securities and Exchange Commission (“SEC”), as well as the financial statements included therein and in subsequent Form 10-Q filings. These filings are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.